抗IgLON5病临床评估复合评分的开发
研究开发抗IgLON5病复合评分(ICS),评估17个症状分属5个临床域,最高69分。在西班牙巴塞罗那和德国GENERATE两个队列共86例患者中测试,ICS与改良Rankin量表(mRS)相关(r=0.429,p<0.001),重测和评定者间信度优良(ICC分别为0.997和0.973)。随访中ICS在恶化患者升高、免疫治疗后改善患者降低。
要点
- ICS评估抗IgLON5病的17个症状,分属延髓、睡眠、运动障碍、认知和其他5个临床域,最高69分。
- ICS与mRS相关(r=0.429,p<0.001),重测信度ICC 0.997(95%CI 0.992-0.999),评定者间信度ICC 0.973(95%CI 0.925-0.990)。
- 随访中ICS在临床稳定患者与诊断时相似(中位11.5 vs 11.5,p=1),恶化患者升高(12.5 vs 18,p=0.012),免疫治疗后改善患者降低(14 vs 10,p=0.007)。
核心结论
- ICS是评估抗IgLON5病不同临床表现的范围和严重程度的有效方法。
研究设计与样本
- 开发抗IgLON5病复合评分(ICS),评估17个症状分属5个临床域(延髓、睡眠、运动障碍、认知和其他),每个症状根据对神经残疾的贡献评0(无/正常)至3或6(严重),最高ICS为69分。
- 在来自2个队列(西班牙巴塞罗那和德国GENERATE)的患者中测试ICS,包括作者亲自诊查的病例(内部)和从转诊神经科医生填写的问卷信息获得ICS的患者(外部)。
主要发现
- 共纳入86例患者(巴塞罗那队列46例;GENERATE队列40例),中位ICS为15(范围2-31)。
- 巴塞罗那队列ICS高于德国队列(18 vs 12,p<0.001),因睡眠和运动障碍域部分评分更高。
- 内部与外部患者ICS无显著差异(15 vs 14,p=0.96)。
- ICS与mRS评分相关(r=0.429,p<0.001)。
- 重测和评定者间信度优良,ICC分别为0.997(95%CI 0.992-0.999)和0.973(95%CI 0.925-0.990)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: To develop a composite score to assess the severity of the multiple symptoms present in anti-IgLON5 disease. METHODS: The anti-IgLON5 disease composite score (ICS) was designed to evaluate 17 symptoms divided into 5 clinical domains (bulbar, sleep, movement disorders, cognition, and others). Each symptom was scored from 0 (absent/normal) to 3 or 6 (severe) depending on the contribution of the symptom to neurologic disability with a maximum ICS of 69. The ICS was tested in patients from 2 cohorts (Barcelona, Spain, and GENERATE, Germany) that included cases personally seen by the authors (internal) and patients whose ICS was obtained from information of questionnaires completed by the referring neurologists (external). Test-retest and interrater reliabilities of the ICS were assessed by the intraclass coefficient (ICC) and the correlation between the ICS and modified Rankin scale (mRS) with the nonparametric Spearman rank coefficient. The Wilcoxon signed rank test was used to compare the ICS at diagnosis of anti-IgLON5 disease and follow-up in a subset of patients with available clinical information. RESULTS: A total of 86 patients (46 from Barcelona cohort; 40 from GENERATE cohort) were included. The median ICS was 15 (range 2-31). The ICS was higher in the Barcelona cohort than in the German cohort (18 vs 12, p < 0.001), due to higher partial scores in sleep and movement disorder domains. There were no significant differences in the ICS between internal and external patients (15 vs 14, p = 0.96). The ICS correlated with the mRS score (r = 0.429, p < 0.001). Test-retest and interrater reliabilities were excellent with an ICC of 0.997 (95% CI 0.992-0.999) and 0.973 (95% CI 0.925-0.990), respectively. ICS was retested during follow-up in 27 patients, and it was similar to that at diagnosis in 10 clinically stable patients (median ICS at diagnosis 11.5 vs 11.5 at follow-up; p = 1), higher in 8 patients who worsened (12.5 vs 18; p = 0.012), and lower in 9 patients who improved after immunotherapy (14 vs 10; p = 0.007). DISCUSSION: The ICS is a valid method to assess the extension and severity of the different clinical manifestations of anti-IgLON5 disease.
引用
- Gaig C, Grüter T, Heidbreder A, et al. Development of a Composite Score for the Clinical Assessment of Anti-IgLON5 Disease. Neurology. 2024. PMID: 38457758. doi:10.1212/WNL.0000000000208101
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。